FDA approves new Kisunla dosing regimen to lower ARIA-E risk
The U.S. Food and Drug Administration (FDA) has approved a more gradual titration dosing schedule for Kisunla (donanemab) for people with early symptomatic Alzheimer’s disease based on evidence that it can lower the risk of ARIA-E, a potentially serious side effect characterized by brain swelling. While the total…